<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04301479</url>
  </required_header>
  <id_info>
    <org_study_id>InCor - HCFMUSP</org_study_id>
    <nct_id>NCT04301479</nct_id>
  </id_info>
  <brief_title>Low Dose Corticosteroid Infusion in Vasoplegia After Cardiac Surgery (CORTIVAS-CS)</brief_title>
  <acronym>CORTIVAS-CS</acronym>
  <official_title>Low Dose Corticosteroid Infusion in Vasoplegia After Cardiac Surgery (CORTIVAS-CS): a Prospective Randomized Double-blinded Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Instituto do Coracao</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Instituto do Coracao</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Vasoplegia is an important determinant for adverse postoperative outcome and is observerd in
      5% to 54% of patients undergoing cardiac surgery using cardiopulmonary bypass (CPB).

      Postoperative vasoplegia is defined as a state with low systemic vascular resistance despite
      a normal or high cardiac output, and the need for vasopressor therapy.

      Steroids attenuate the inflammatory response to cardiopulmonary bypass,but their effect on
      clinical outcomes is uncertain.

      This is a double-blinded, randomized, clinical trial designed to determine the efficacy of
      low dose corticosteroid infusion in vasopressor free-days in vasoplegia after cardiac
      surgery.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 2020</start_date>
  <completion_date type="Anticipated">March 2021</completion_date>
  <primary_completion_date type="Anticipated">March 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Vasopressors-free days</measure>
    <time_frame>30 days</time_frame>
    <description>Days free of vasopressors up to day 30</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>30 days mortallity</measure>
    <time_frame>30 days</time_frame>
    <description>The number of deaths within 30 days of surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ICU length of stay</measure>
    <time_frame>30 days</time_frame>
    <description>Duration in days from the date of the ICU admission to the date of ICU discharge</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Infection complication</measure>
    <time_frame>30 days</time_frame>
    <description>Rate of new infection or septic shock within 30 days after randomization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute myocardial infarction</measure>
    <time_frame>30 days</time_frame>
    <description>We will compare the incidence of acute myocardial infarction between groups within 30 days after randomization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Atrial fibrillation</measure>
    <time_frame>30 days</time_frame>
    <description>We will compare the incidence of atrial fibrillation between groups within 30 days after randomization</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Duration of mechanical ventilation</measure>
    <time_frame>30 days</time_frame>
    <description>Duration in hours from the intraoperative intubation to postoperative extubation</description>
  </other_outcome>
  <other_outcome>
    <measure>Post-operative length of stay</measure>
    <time_frame>30 days</time_frame>
    <description>Post-operative LOS is the duration in days from the date of the end of surgery to the date of discharge from hospital.</description>
  </other_outcome>
  <other_outcome>
    <measure>Mesenteric ischemia</measure>
    <time_frame>30 days</time_frame>
    <description>We will compare the atrial fibrillation between groups within 30 days after randomization</description>
  </other_outcome>
  <other_outcome>
    <measure>Acute respiratory distress syndrome</measure>
    <time_frame>30 days</time_frame>
    <description>We will compare the incidence of acute respiratory distress syndrome between groups within 30 days after randomization</description>
  </other_outcome>
  <other_outcome>
    <measure>Stroke</measure>
    <time_frame>30 days</time_frame>
    <description>We will compare the incidence of stroke between groups within 30 days after randomization</description>
  </other_outcome>
  <other_outcome>
    <measure>Hyperglycemia</measure>
    <time_frame>Up to 72 hours</time_frame>
    <description>Peak of capillary blood glucose glycemia up to 72 hours after the start the protocol solution</description>
  </other_outcome>
  <other_outcome>
    <measure>180 days mortallity</measure>
    <time_frame>180 days</time_frame>
    <description>The number of deaths within 180 days of surgery</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">140</enrollment>
  <condition>Vasoplegia</condition>
  <condition>Cardiac Surgery</condition>
  <arm_group>
    <arm_group_label>Steroid</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients assigned for steroid group will receive 200 mg of hydrocortisone diluted in 120 mL of saline at an infusion rate of 5mL/hr for 3 days or shock reversal, defined by systolic arterial pressure &gt; 90 mmHg for 12 hours after vasopressor weaning without fluid expansion.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients assigned for control group will receive 120 mL of saline solution at a rate of 5mL/hr for 3 days or shock reversal, defined by systolic arterial pressure &gt; 90 mmHg for 12 hours after vasopressor weaning without fluid expansion.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>hydrocortisone sodium succinate</intervention_name>
    <description>Steroid group will receive 200 mg of hydrocortisone diluted in 120 mL of saline at an infusion rate of 5mL/hr for 3 days or shock reversal</description>
    <arm_group_label>Steroid</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saline</intervention_name>
    <description>Control group will receive 120 mL of saline solution at a rate of 5mL/hr for 3 days or shock reversal</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Cardiac surgery with cardiopulmonary bypass

          -  Norephinerine treatment in ICU with dose great or equal than 0,1 mcg/kg/min to
             maintain or restore a MAP over 70 mmHg for at least 30 minutes within 24 hours after
             surgery

        Exclusion Criteria:

          -  Preoperative vasopressor use (within 72 hours prior to surgery)

          -  Preoperative steroids use (within 7 days prior to surgery)

          -  Presence of ventricular assist device other than intraaortic ballon pump

          -  Transplant procedures

          -  Emergency procedures

          -  Aortic repairs

          -  Congenital procedures

          -  Endocarditis

          -  Bacterial or fungal infection in the preceding 30 days

          -  Active neoplasia

          -  Pregnancy

          -  Recent history of gastrointestinal bleeding

          -  Allergy or intolerance to steroids

          -  Participation in other study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Incor - Heart Institute - University of Sao Paulo</name>
      <address>
        <city>Sao Paulo</city>
        <zip>05403000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>February 27, 2020</study_first_submitted>
  <study_first_submitted_qc>March 5, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 10, 2020</study_first_posted>
  <last_update_submitted>March 5, 2020</last_update_submitted>
  <last_update_submitted_qc>March 5, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Instituto do Coracao</investigator_affiliation>
    <investigator_full_name>Filomena R B G Galas</investigator_full_name>
    <investigator_title>Associate Professor of Anesthesiology at University SÃ£o Paulo Medical School</investigator_title>
  </responsible_party>
  <keyword>vasoplegia</keyword>
  <keyword>cardiac surgery</keyword>
  <keyword>steroids</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vasoplegia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hydrocortisone</mesh_term>
    <mesh_term>Hydrocortisone 17-butyrate 21-propionate</mesh_term>
    <mesh_term>Hydrocortisone acetate</mesh_term>
    <mesh_term>Hydrocortisone hemisuccinate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

